MWNA
INZY

Marshall Wace North America’s Inozyme Pharma INZY Stock Holding History

Marshall Wace North America’s Portfolio INZY Stock Details INZY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-9,514
Closed -$250K – 1429
2020
Q3 		$250K Buy
+9,514
New +$236K ﹤0.01% 1099

Other funds holding INZY

NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
PBPIA
Pivotal bioVenture Partners Investment Advisor San Francisco, California $280M AUM 181.4% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
CA
CHI Advisors New York $252M AUM 56.99% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Marshall Wace North America's INZY Position: Q4 2020 in Review

Marshall Wace North America sold out of Inozyme Pharma (INZY) in Q4 2020, closing a stake of 9,514 shares — an estimated $250K sold.

Marshall Wace North America first reported a position in INZY in Q3 2020 and held it in 1 quarter. The position peaked at $250K in Q3 2020. 54 funds tracked by Wall St. Rank hold INZY as of Q4 2020.

  • Marshall Wace North America reported no remaining Inozyme Pharma position as of Q4 2020 after selling out during the quarter.
  • Marshall Wace North America sold 9,514 Inozyme Pharma shares in Q4 2020, an estimated $250K.
  • Marshall Wace North America first reported a position in Inozyme Pharma in Q3 2020 and held it in 1 quarter.
  • Marshall Wace North America's Inozyme Pharma position peaked at $250K in Q3 2020.
  • 54 funds tracked by Wall St. Rank held Inozyme Pharma as of Q4 2020.

Based on Marshall Wace North America's 13F filing for Q4 2020, filed 16 Feb 2021.